United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

United Therapeutics Corporation (NASDAQ ... and collaborates with other companies on various drug development projects. It is also one of the 10 best healthcare stocks for long-term investment.

It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...

We expect an in-line return from the stock in the next few months. United Therapeutics is part of the Zacks Medical - Drugs industry. Over the past month, Zoetis (ZTS), a stock from the same ...